Your session is about to expire
← Back to Search
Paclitaxel + Nilotinib for Cancer
Study Summary
This trial is testing a combination of oral nilotinib plus paclitaxel given by IV and directly into the abdomen to see if it can reduce tumors enough for people to have surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have moderate to severe numbness, tingling, or pain in my hands or feet.My cancer, which started in the peritoneum and is not mucinous, has been confirmed by pathology.I have had a lot of fluid in my abdomen or more than two fluid removal procedures recently.I cannot have surgery to reduce my tumor, due to extensive spread or involvement.My cancer's growth can be tracked with specific medical tests.I am not taking medication that affects heart rhythm or interferes with certain liver enzymes.My liver is severely damaged (Child-Pugh Class C).I agree to use birth control during and for 3 months after the study.My heart's electrical activity (QTcF interval) is normal or I don't have congenital long QT syndrome.I have not had chemotherapy directly into my abdomen in the last 6 months.My organs and bone marrow are working well.I have HIV with a detectable viral load or take medications that affect heart rhythm or interact with certain enzymes.I haven't had chemotherapy or major surgery in the last 12 weeks.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I am 18 years old or older.I have had chemotherapy but my cancer did not respond.I can take care of myself but may not be able to do heavy physical work.
- Group 1: 1/ IP Catheter Placement and Bidirectional Chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Paclitaxel a secure option for individuals?
"Paclitaxel received a safety score of 2 due to existing evidence in Phase 2 trials that demonstrate its security, but no proof yet demonstrating the medication's efficacy."
What is the aggregate figure of participants enrolled in this trial?
"Affirmative. According to the clinicaltrials.gov website, this medical experiment is currently in search of participants and was first posted on October 13th 2022. The study has since been revised as recently as October 28th 2022, with 70 people needed at one location for it's completion."
Are applications for this medical research still being accepted?
"Yes, the information accessible from clinicaltrials.gov confirms that this medical exploration is presently recruiting patients. The trial was initially published on October 13th 2022 and had changes applied to it most recently in late October of the same year. 70 individuals are required for participation at a single site."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- National Institutes of Health Clinical Center: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger